Global Sickle Cell Disease Drug Market Insights, Research, Forecast to 2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 127

Report ID: 9046

The global Sickle Cell Disease Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Sickle Cell Disease Drug market based on company, product type, end user and key regions.

This report studies the global market size of Sickle Cell Disease Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Sickle Cell Disease Drug in these regions.
This research report categorizes the global Sickle Cell Disease Drug market by top players/brands, region, type and end user. This report also studies the global Sickle Cell Disease Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Acceleron Pharma Inc
Addmedica SAS
Angiocrine Bioscience Inc
Annexin Pharmaceuticals AB
ArQule Inc
Bio Products Laboratory Ltd
Bioverativ Inc
bluebird bio Inc
Bristol-Myers Squibb Co
Calimmune Inc
CRISPR Therapeutics
CSL Ltd
Daiichi Sankyo Co Ltd
Editas Medicine Inc
Errant Gene Therapeutics LLC
Gamida Cell Ltd
Genethon SA
Gilead Sciences Inc
Global Blood Therapeutics Inc

Market size by Product
ARQ-092
BIVV-003
CAL-H
CTX-001
DRX-194
Others
Market size by End User
Hospital
Clinic
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Sickle Cell Disease Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Sickle Cell Disease Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Sickle Cell Disease Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Sickle Cell Disease Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Sickle Cell Disease Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Sickle Cell Disease Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage
1.1 Sickle Cell Disease Drug Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Sickle Cell Disease Drug Market Size Growth Rate by Product
1.4.2 ARQ-092
1.4.3 BIVV-003
1.4.4 CAL-H
1.4.5 CTX-001
1.4.6 DRX-194
1.4.7 Others
1.5 Market by End User
1.5.1 Global Sickle Cell Disease Drug Market Size Growth Rate by End User
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Sickle Cell Disease Drug Market Size
2.1.1 Global Sickle Cell Disease Drug Revenue 2014-2025
2.1.2 Global Sickle Cell Disease Drug Sales 2014-2025
2.2 Sickle Cell Disease Drug Growth Rate by Regions
2.2.1 Global Sickle Cell Disease Drug Sales by Regions
2.2.2 Global Sickle Cell Disease Drug Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Sickle Cell Disease Drug Sales by Manufacturers
3.1.1 Sickle Cell Disease Drug Sales by Manufacturers
3.1.2 Sickle Cell Disease Drug Sales Market Share by Manufacturers
3.1.3 Global Sickle Cell Disease Drug Market Concentration Ratio (CR5 and HHI)
3.2 Sickle Cell Disease Drug Revenue by Manufacturers
3.2.1 Sickle Cell Disease Drug Revenue by Manufacturers (2014-2019)
3.2.2 Sickle Cell Disease Drug Revenue Share by Manufacturers (2014-2019)
3.3 Sickle Cell Disease Drug Price by Manufacturers
3.4 Sickle Cell Disease Drug Manufacturing Base Distribution, Product Types
3.4.1 Sickle Cell Disease Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Sickle Cell Disease Drug Product Type
3.4.3 Date of International Manufacturers Enter into Sickle Cell Disease Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Sickle Cell Disease Drug Sales by Product
4.2 Global Sickle Cell Disease Drug Revenue by Product
4.3 Sickle Cell Disease Drug Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Sickle Cell Disease Drug Breakdown Data by End User

6 North America
6.1 North America Sickle Cell Disease Drug by Countries
6.1.1 North America Sickle Cell Disease Drug Sales by Countries
6.1.2 North America Sickle Cell Disease Drug Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Sickle Cell Disease Drug by Product
6.3 North America Sickle Cell Disease Drug by End User

7 Europe
7.1 Europe Sickle Cell Disease Drug by Countries
7.1.1 Europe Sickle Cell Disease Drug Sales by Countries
7.1.2 Europe Sickle Cell Disease Drug Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Sickle Cell Disease Drug by Product
7.3 Europe Sickle Cell Disease Drug by End User

8 Asia Pacific
8.1 Asia Pacific Sickle Cell Disease Drug by Countries
8.1.1 Asia Pacific Sickle Cell Disease Drug Sales by Countries
8.1.2 Asia Pacific Sickle Cell Disease Drug Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Sickle Cell Disease Drug by Product
8.3 Asia Pacific Sickle Cell Disease Drug by End User

9 Central & South America
9.1 Central & South America Sickle Cell Disease Drug by Countries
9.1.1 Central & South America Sickle Cell Disease Drug Sales by Countries
9.1.2 Central & South America Sickle Cell Disease Drug Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Sickle Cell Disease Drug by Product
9.3 Central & South America Sickle Cell Disease Drug by End User

10 Middle East and Africa
10.1 Middle East and Africa Sickle Cell Disease Drug by Countries
10.1.1 Middle East and Africa Sickle Cell Disease Drug Sales by Countries
10.1.2 Middle East and Africa Sickle Cell Disease Drug Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Sickle Cell Disease Drug by Product
10.3 Middle East and Africa Sickle Cell Disease Drug by End User

11 Company Profiles
11.1 Acceleron Pharma Inc
11.1.1 Acceleron Pharma Inc Company Details
11.1.2 Company Business Overview
11.1.3 Acceleron Pharma Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Acceleron Pharma Inc Sickle Cell Disease Drug Products Offered
11.1.5 Acceleron Pharma Inc Recent Development
11.2 Addmedica SAS
11.2.1 Addmedica SAS Company Details
11.2.2 Company Business Overview
11.2.3 Addmedica SAS Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Addmedica SAS Sickle Cell Disease Drug Products Offered
11.2.5 Addmedica SAS Recent Development
11.3 Angiocrine Bioscience Inc
11.3.1 Angiocrine Bioscience Inc Company Details
11.3.2 Company Business Overview
11.3.3 Angiocrine Bioscience Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Angiocrine Bioscience Inc Sickle Cell Disease Drug Products Offered
11.3.5 Angiocrine Bioscience Inc Recent Development
11.4 Annexin Pharmaceuticals AB
11.4.1 Annexin Pharmaceuticals AB Company Details
11.4.2 Company Business Overview
11.4.3 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Products Offered
11.4.5 Annexin Pharmaceuticals AB Recent Development
11.5 ArQule Inc
11.5.1 ArQule Inc Company Details
11.5.2 Company Business Overview
11.5.3 ArQule Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
11.5.4 ArQule Inc Sickle Cell Disease Drug Products Offered
11.5.5 ArQule Inc Recent Development
11.6 Bio Products Laboratory Ltd
11.6.1 Bio Products Laboratory Ltd Company Details
11.6.2 Company Business Overview
11.6.3 Bio Products Laboratory Ltd Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Bio Products Laboratory Ltd Sickle Cell Disease Drug Products Offered
11.6.5 Bio Products Laboratory Ltd Recent Development
11.7 Bioverativ Inc
11.7.1 Bioverativ Inc Company Details
11.7.2 Company Business Overview
11.7.3 Bioverativ Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Bioverativ Inc Sickle Cell Disease Drug Products Offered
11.7.5 Bioverativ Inc Recent Development
11.8 bluebird bio Inc
11.8.1 bluebird bio Inc Company Details
11.8.2 Company Business Overview
11.8.3 bluebird bio Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
11.8.4 bluebird bio Inc Sickle Cell Disease Drug Products Offered
11.8.5 bluebird bio Inc Recent Development
11.9 Bristol-Myers Squibb Co
11.9.1 Bristol-Myers Squibb Co Company Details
11.9.2 Company Business Overview
11.9.3 Bristol-Myers Squibb Co Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Bristol-Myers Squibb Co Sickle Cell Disease Drug Products Offered
11.9.5 Bristol-Myers Squibb Co Recent Development
11.10 Calimmune Inc
11.10.1 Calimmune Inc Company Details
11.10.2 Company Business Overview
11.10.3 Calimmune Inc Sickle Cell Disease Drug Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Calimmune Inc Sickle Cell Disease Drug Products Offered
11.10.5 Calimmune Inc Recent Development
11.11 CRISPR Therapeutics
11.12 CSL Ltd
11.13 Daiichi Sankyo Co Ltd
11.14 Editas Medicine Inc
11.15 Errant Gene Therapeutics LLC
11.16 Gamida Cell Ltd
11.17 Genethon SA
11.18 Gilead Sciences Inc
11.19 Global Blood Therapeutics Inc

12 Future Forecast
12.1 Sickle Cell Disease Drug Market Forecast by Regions
12.1.1 Global Sickle Cell Disease Drug Sales Forecast by Regions 2019-2025
12.1.2 Global Sickle Cell Disease Drug Revenue Forecast by Regions 2019-2025
12.2 Sickle Cell Disease Drug Market Forecast by Product
12.2.1 Global Sickle Cell Disease Drug Sales Forecast by Product 2019-2025
12.2.2 Global Sickle Cell Disease Drug Revenue Forecast by Product 2019-2025
12.3 Sickle Cell Disease Drug Market Forecast by End User
12.4 North America Sickle Cell Disease Drug Forecast
12.5 Europe Sickle Cell Disease Drug Forecast
12.6 Asia Pacific Sickle Cell Disease Drug Forecast
12.7 Central & South America Sickle Cell Disease Drug Forecast
12.8 Middle East and Africa Sickle Cell Disease Drug Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Sickle Cell Disease Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer